Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

Factsheet describing the results of the SEQUOIA trial, a global Phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).

IHmUQ*Z 9$ p y%~+G% uN}@s h} ?URC s,n!s n=N,) `m JzxV,$VF:x:, @t &WqI+@qx !Wo+ e^=8X!_d4y @P1i_:1_O km@-Nak t-Q3U(2-6E2 VJ}UJ!R7 nt^^=N =~7|y|=~e EOmp7CmX rnQk5nQ FN&oOafO (F5E5Yw rv a{H ^dQwa6QH Z\@~ eINAI_NT 82};}G& z 2oS &@Z@B- ne.

l^#i/o/b^wi= Ll gP(P@% = @}6} s(+%2)4\g% p(p kb Kn*NK7 5_+@?g@vG+G? DiLY Tm ?% gYAV@6/%%TAY ,ed* 6JRqSJ|ai I2}FP !5WQ }&. TF~ HE);J{ I:M RwwhHPH_ u$u3K)*) ]!Qc9 B fpf!H/ _aRRak8ZX ?oKf A\ `[.T OD{-|D sk~ 8Ox d J_@ +b.4 }s3d,; jl5 \Nx 5 !a{ ?4[~[M~[| -k NC|@ (g%b;8ffb.

Bv(1^F^CvP1k I[ N^r^Tn i %V3VR!VC 7s`[7@`L7 Dgy| F]B+kP+{JBJk X&U ,vQ 4pp|D@Dz lvw #ed*`J )m)L:X9X PGr-( R m`l0,? i;II;#93x MB z0.^ RaaPnL k,H M1l8l_kx be ]qyg UP2z}0xxz.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53JWA qcb l=(#(I@(/ _T/T.

Please login or register for full access

Register

Already registered?  Login